{"title":"MRI-based stratification reduces the risk of overdiagnosis of prostate cancer","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00957-0","DOIUrl":null,"url":null,"abstract":"<p>Men with a serum PSA of >3.0 ng/ml are typically referred for further diagnostic investigations for prostate cancer; however, many either will not have the disease or will have low-risk tumours and might have adverse events from unnecessary diagnostic procedures and/or overtreatment. Now, an update from the ongoing GÖTEBORG-2 study demonstrates that men without suspicious lesions detected on MRI of the prostate can safely forego further diagnostic procedures.</p><p>In GÖTEBORG-2, a total of 13,153 men 50–60 years of age are undergoing serum PSA monitoring at 2, 4 or 8 years after initial testing depending on baseline results, with a serum PSA of >3.0 ng/ml at any round of testing as the threshold for further investigation. These men were randomly allocated 1:1 to undergo prostate MRI followed by systematic biopsy sampling regardless of MRI findings versus only targeted biopsy sampling if suspicious lesions were detected on MRI. Detection of clinically insignificant (International Society of Urological pathology (ISUP) grade 1) prostate cancer was the primary end point. Detection of clinically significant (ISUP grade ≥2) prostate cancer was a secondary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00957-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Men with a serum PSA of >3.0 ng/ml are typically referred for further diagnostic investigations for prostate cancer; however, many either will not have the disease or will have low-risk tumours and might have adverse events from unnecessary diagnostic procedures and/or overtreatment. Now, an update from the ongoing GÖTEBORG-2 study demonstrates that men without suspicious lesions detected on MRI of the prostate can safely forego further diagnostic procedures.
In GÖTEBORG-2, a total of 13,153 men 50–60 years of age are undergoing serum PSA monitoring at 2, 4 or 8 years after initial testing depending on baseline results, with a serum PSA of >3.0 ng/ml at any round of testing as the threshold for further investigation. These men were randomly allocated 1:1 to undergo prostate MRI followed by systematic biopsy sampling regardless of MRI findings versus only targeted biopsy sampling if suspicious lesions were detected on MRI. Detection of clinically insignificant (International Society of Urological pathology (ISUP) grade 1) prostate cancer was the primary end point. Detection of clinically significant (ISUP grade ≥2) prostate cancer was a secondary end point.
期刊介绍:
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.